News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Jul 11, 2019Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis
Boonton, NJ – July 11, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies,...
- Jul 10, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today an update relative to the Company’s NATESTO® business....
- Jul 08, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript to the Journal of the...
- Jul 01, 2019
FARMINGDALE, N.Y., July 01, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jun 28, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 28, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its...
- Jun 27, 2019Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
Boonton, NJ – June 27, 2019 – Enteris BioPharma, Inc. a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, congratulates...
- Jun 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening...
- Jun 27, 2019
Acerus Pharmaceuticals Corporation ("Acerus") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario. The total number of...
- Jun 26, 2019–Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway— — TADFIN is a First Novel Combination Formulation of Tadalafil and Finasteride for the Treatment of BPH with NDA Submission Anticipated in Summer of 2020–
MIAMI, June 26, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jun 20, 2019
FARMINGDALE, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical...
- Jun 13, 2019Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients
DEER PARK, Ill., June 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jun 13, 2019Moving the industry Beyond Surface Technology and into Mechanobiology
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant TechnologyTM, announced today that it has closed a substantial round of...
- Jun 12, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 12, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 11, 2019Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 11, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at...
- Jun 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus...
- Jun 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 04, 2019— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical Development Strategy —
MIAMI, June 04, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jun 04, 2019--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families--
LISBON, Portugal--(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 03, 2019
FARMINGDALE, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jun 02, 2019
LISBON, Portugal--(BUSINESS WIRE)--Jun. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented...
- May 30, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the...
- May 29, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that President and CEO Todd Norbe and Executive Vice President and CFO John Beaver are scheduled to present at the 9th
- May 28, 2019
MIAMI, May 28, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 28, 2019Enteris BioPharma to Present at New Rhein Healthcare Inaugural Industry Day 2019
Boonton, NJ – May 28, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- May 24, 2019– Full Results from Phase 3 ARTEMIS Study Will Be Featured –
BRISBANE, Calif.--(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 21, 2019-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure --
NEW ORLEANS--(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 20, 2019
FARMINGDALE, N.Y., May 20, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- May 20, 2019
Please see supporting documents for the information about a proposed settlement of a derivative action involving the company.
- May 16, 2019- Company Enters into Commercial Supply Agreement for AR101 -
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019Hear from leading experts, including keynote speaker Gordon J. Christensen DDS, MSD, PhD, on the latest trends and innovations in dentistry
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is proud to announce that it will host the Advancing Dentistry Symposium in San Diego, California on October 18-19, 2019. The...
- May 15, 2019— Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising – — Strong Financial Results for Q2 and YTD FY 2019 — — Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET –
MIAMI, May 15, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU) an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 15, 2019
DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 15, 2019Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
Dallas, TX, May 15, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.
- May 13, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three-month period ended March...
- May 13, 2019
Lake Forest, CA – May 13, 2019 – Tenex Health, Inc., a privately held U.S.-based medical technology company providing healthcare professionals with minimally invasive technologies to treat...
- May 09, 2019First Quarter U.S. Laser Revenue Increased 18% Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.3 million for the first quarter ended March 31, 2019, an increase of 3% compared to the first...
- May 08, 2019
MIAMI, May 08, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 08, 2019Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 08, 2019
FARMINGDALE, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- May 08, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB...
- May 07, 2019– Four Products Currently Under Review with the FDA –
DEER PARK, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens. The...
- May 06, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release first quarter 2019 financial and operating results on Thursday, May 9, 2019 after the close...
- May 02, 2019Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes
FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical...
- May 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Apr 30, 2019
DEER PARK, Ill., April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Apr 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has engaged Paradigm Capital Inc. (“Paradigm”) as its...
- Apr 24, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview...
- Apr 10, 2019
FARMINGDALE, N.Y., April 10, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Apr 09, 2019BIOLASE and TeamSmile Expand Initiative of Oral Health Day to Students in Kansas City Public SchoolsPlayers and mascot "Blue the Dog" from Sporting Kansas City will be in attendance to meet and greet the students and support the program
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Sporting...
- Apr 03, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that
- Mar 29, 2019Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.
Dallas, TX, March 29, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Mar 29, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”)...
- Mar 27, 2019Chargers wide receiver Geremy Davis, running back Justin Jackson and the Charger Girls to meet the students and support necessary cause
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Los...
- Mar 25, 2019NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019
DEER PARK, Ill., March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Mar 25, 2019-- Company Intends to Submit European MAA in Mid-2019 --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 18, 2019-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 14, 2019FDA Previously Granted DS-200 Fast Track Designation
DEER PARK, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
- Mar 12, 2019
MIAMI, March 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Mar 11, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will be presenting at the second annual LD Micro Virtual Investor Conference on Wednesday, March 13th at...
- Mar 06, 2019
FARMINGDALE, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 05, 2019Enteris’ lead program, Ovarest®, is designed to address a key endometriosis patient need by enabling the oral delivery of leuprolide
Boonton, NJ – March 5, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- Mar 05, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended...
- Mar 05, 2019Fourth Quarter U.S. Laser Revenue Increased 51% Year Over Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $13.0 million and $46.2 million for the fourth quarter and year ended December 31, 2018,...
- Mar 04, 2019Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role
FARMINGDALE, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 04, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with...
- Feb 28, 2019FDA decision on AR101 BLA filing acceptance expected by end of March
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 28, 2019BIOLASE appoints Sinclair Dental, the fastest growing full-service dental supply company in Canada, as the exclusive distributor and representative for the sales, service and support of BIOLASE's products
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced the appointment of Sinclair Dental Co. Ltd, the fastest growing dental supply company in Canada with more than 600...
- Feb 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) announced today two updates relative to the Company’s NATESTO® business. First, the...
- Feb 26, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019...
- Feb 25, 2019— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 25, 2019
FARMINGDALE, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 21, 2019
DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 21, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 19, 2019If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind
LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton...
- Feb 13, 2019— Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling — — Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET —
MIAMI, Feb. 13, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 12, 2019
MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 11, 2019Transaction adds an additional potential 2019 product launch to Eton’s pipeline
DEER PARK, Ill., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 07, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter 2018 financial and operating results on Tuesday, March 5, 2019 after the close...
- Feb 06, 2019
MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 06, 2019
FARMINGDALE, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 04, 2019— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 04, 2019Feb. 4 event will include meet-and-greets with Dallas Mavericks players, Mavs ManiAACs, dancers, and families will learn more about the latest dental technologies, including laser treatments
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, the Dallas Mavericks and TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved...
- Jan 29, 2019On the heels of a successful co-promotion during the recent Greater New York Dental Meeting, the two companies will offer exclusive deals and product samples for complimentary product lines at the Yankee Dental Congress and Chicago Midwinter Meeting
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today a joint product promotion with Hu-Friedy, the global leader in the manufacturing of dental instruments, at two...
- Jan 25, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has received a Notice of Deficiency-Withdrawal Letter...
- Jan 24, 2019New Drug Application expected to be filed in 2019
DEER PARK, Ill., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jan 22, 2019–Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End– — Drug Addresses Significant Unmet Medical Need —
MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a...
- Jan 22, 2019
FARMINGDALE, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jan 18, 2019— Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning —
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Jan 15, 2019
MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster...
- Jan 14, 2019Company Plans to Submit NDA in 2019
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary...
- Jan 11, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has reported an anticipated shortage of certain doses of...
- Jan 04, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Jan 04, 2019--Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events --
LISBON, Portugal--(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jan 04, 2019
Keystone Dental Inc. ("Keystone"), the largest independent dental implant company operating in North America, has entered into a definitive agreement to merge via a stock exchange transaction with...
- Jan 03, 2019The Los Angeles Chargers Girls will also be visiting to help bring awareness to this community-driven initiative
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, and TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children and the...
- Jan 02, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...